Health and Healthcare Systems

Malaria vaccines provide new hope in fight against the disease 

Mosquitoes in a petri dish, as the WHO approves a malaria vaccine

Nigeria joins Ghana to become the second country to approve a malaria vaccine for children. Image: REUTERS/Jim Young (UNITED STATES) - GM1DWLPQTCAA

Kate Whiting
Senior Writer, Forum Agenda
Our Impact
What's the World Economic Forum doing to accelerate action on Health and Healthcare Systems?
The Big Picture
Explore and monitor how Global Health is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Global Health

This article is part of: Centre for Health and Healthcare

Listen to the article

This article was first published in October 2021, was updated in September 2022, and again on 14 April 2023 and 21 April 2023.

  • In 2021, the World Health Organization approved a malaria vaccine for use in children for the first time.
  • Ghana, and now Nigeria, have become the first countries to approve a new malaria vaccine for use in children aged between five months and three years old.
  • Malaria killed 274,000 children under five in 2019.
  • Here, the WHO's Director of the Global Malaria Programme, Dr Pedro Alonso, explains the vaccine breakthrough.

In a groundbreaking first, Ghana approved a new malaria vaccine for use in young children on 13 April.

And now Nigeria, Africa's most populous nation, has provisionally approved use of the vaccine less than a week later.

In 2019, 386,000 Africans died from malaria, of which 274,000 were children under five, according to the World Health Organization (WHO).

In 2021, the WHO approved a malaria vaccine for children for the first time, after a successful pilot scheme in three African countries: Ghana, Kenya and Malawi.

RTS,S – or Mosquirix – is a vaccine developed by British drugmaker GlaxoSmithKline, which acts against P. falciparum, the most deadly malaria parasite globally, and the most prevalent in Africa.

WHO Director-General Dr Tedros Adhanom Ghebreyesus called it a "historic moment" and a "breakthrough for science, child health and malaria control".

“Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year,” he added.

Ghana and Nigeria are the first countries to approve new malaria vaccine

Mosquirix has paved the way for a more potent R21 vaccine developed by the University of Oxford, with evidence showing vaccine effectiveness at as much as 80%. Combined with a manufacturing advantage, the malaria vaccine has been described as having "world-changing" potential.

Ghana is the first country to officially approve the use of the new R21 vaccine. Its Food and Drugs Authority, which has seen data from a recent trial, has approved the vaccine's use in children aged between five months to three years old.

And now provisional approval for the vaccine has been granted by Nigeria's National Agency for Food and Drug Administration and Control. It's the country most affected by malaria, accounting for over 30% of global malaria deaths, according to the WHO.

"We expect R21 to make a major impact on malaria mortality in children in the coming years, and in the longer term [it] will contribute to [the] overall final goal of malaria eradication and elimination," Professor Adrian Hill, director of the Jenner Institute at the University of Oxford, where the vaccine was invented, told the BBC.

Talking in 2021, the World Economic Forum's Head, Shaping the Future of Health and Healthcare, Shyam Bishen, said: “Malaria is one of the biggest infectious diseases which kills close to half a million people every year. A more effective malaria vaccine with 80% efficacy which can be produced on a larger scale at an affordable price would be a great tool in our fight against this deadly vector-borne disease."

Bishen continued, “Along with other malaria-fighting measures, this vaccine could help save tens of thousands of lives every year. We also need to make sure there are investments and resources available for further development and delivery to those who need it most, such as communities in Africa and Southeast Asia”.

A malaria vaccine has been approved by WHO
Malaria killed 274,000 African children under five in 2019. Image: Our World in Data

The WHO's Global Malaria Programme Director, Dr Pedro Alonso, explained the vaccine breakthrough to Science in 5. That interview spotlights how the latest developments could address some of the biggest challenges in efficacy, manufacturing and rollout.

What is the potential of this malaria vaccine?

"We are at a historical point in time. A first malaria vaccine is being recommended for broad-scale use among children in Africa to help prevent malaria in this group.

"The vaccine reaches this stage at a critical point in time in our fight against malaria. Malaria is probably the largest killer of humans along history. We have seen unprecedented progress this century, which resulted in 7 million deaths averted...

"But the stark truth is that for the past four or five years, progress has plateaued. We still have more than 200 million malaria cases in people living in malaria-endemic countries every year. We have more than 400,000 deaths due to malaria every year - and the brunt of the disease and death is carried by African children."


What is the World Economic Forum doing about access to vaccines?

How safe is the malaria vaccine?

"It's a vaccine developed in Africa, with strong engagement of African scientists and aimed to prevent malaria disease and death among African children.

"The malaria vaccine has now been used among 800,000 children as part of our pilot implementation programmes and builds on phase 3 trial data that has been examined by the European Medicines Agency, that issued a positive recommendation.

"We are reassured on the good safety profile of this vaccine. It is a safe and efficacious vaccine that can contribute to saving lives and preventing disease."

Have you read?

What are the challenges of rolling out the malaria vaccine?

"We've found over the past two-and-a-half years of rolling out the malaria vaccine in the pilot programmes, there's very strong demand, very good acceptability by the populations and, even in the face of COVID-19, we reached very high levels of coverage within a short period of time.

"That speaks of the fundamental value and acceptance of vaccines in general and of a malaria vaccine, particularly in Africa.

"There are a number of steps we still need to go through. The funding to secure the supply of this vaccine to African countries still needs to be worked out, but we are optimistic.

"We cannot imagine a situation where international solidarity will not generate the financial resources to allow this vaccine to reach those that need it.

"In the face of COVID-19, the resilience of health systems and particularly of vaccine delivery mechanisms in Africa gives us hope that this vaccine will be able to reach those ultimate beneficiaries – young children."

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Antimicrobial resistance is a leading cause of global deaths. Now is the time to act

Dame Sally Davies, Hemant Ahlawat and Shyam Bishen

May 16, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum